PRIMARY STUDY
Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial
Key Findings: Combining ultramicronized palmitoylethanolamide and Luteolin with olfactory training (OT) was more effective than OT alone, in treating smell alteration following COVID-19 infection, however, the efficacy for parosmia was limited. UmpEA-LUT is useful in neuro-inflammation but has limited/no effect on peripheral damage.
Type of Study: Clinical Trial
Study Sample Size: 130
Study Result: Positive
Research Location(s): Italy
Year of Pub: 2023
Cannabinoids Studied: Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile,
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Dosage Form: co-ultra-micronized palmitoylethanolamide and luteolin oral supplement
Dosing Regimen: co-ultra-micronized PEA 700 mg and Luteolin 70 mg (umPEA-LUT) = ultraPEA-LUT oral supplement
Starting Dose: single dose 5–10 min before breakfast in combination with daily olfactory training
Treatment Duration: 90 days
Clinical Relevance: UmpEA-LUT is useful in neuro-inflammation but has limited/no effect on peripheral damage.
Citation: Di Stadio A, et al. Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial. Biomedicines. 2023; 11:(unknown pages). doi: 10.3390/biomedicines11041109
Authors: Di Stadio A, Cantone E, De Luca P, Di Nola C, Massimilla EA, Motta G, La Mantia I, Motta G
